Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price objective reduced by UBS AG from $535.00 to $500.00 in a research report issued to clients and investors on Thursday, www.benzinga.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. UBS AG’s price target indicates a potential upside of 14.11% from the stock’s previous close.

REGN has been the subject of a number of other research reports. Morgan Stanley restated an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 23rd. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 14th. Leerink Swann restated an “outperform” rating and issued a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Finally, Citigroup Inc. upped their target price on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $490.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 EPS. The business’s revenue was up 21.2% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/21/regeneron-pharmaceuticals-inc-regn-price-target-cut-to-500-00-by-analysts-at-ubs-ag.html.

In other news, major shareholder Sanofi purchased 166,415 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman P Roy Vagelos sold 15,191 shares of the stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $470.15, for a total transaction of $7,142,048.65. Following the completion of the sale, the chairman now owns 329,543 shares in the company, valued at $154,934,641.45. The disclosure for this sale can be found here. Insiders sold a total of 85,968 shares of company stock worth $40,699,948 over the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. raised its position in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares during the period. FNY Managed Accounts LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $140,000. FNY Partners Fund LP raised its position in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares during the period. Finally, Alpha Windward LLC raised its position in shares of Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 1 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.